Status:
COMPLETED
Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure
Lead Sponsor:
Piergiuseppe Agostoni
Conditions:
Heart Failure, Congestive
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes ex...
Detailed Description
Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function inc...
Eligibility Criteria
Inclusion
- New York Heart Association (NYHA) class I and II heart failure
- Chronic ACE-inhibitor treatment
Exclusion
- Aspirin treatment in the previous 2 months
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00361127
Start Date
August 1 2006
End Date
December 1 2013
Last Update
January 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Cardiologico Monzino
Milan, Italy, 20138